Latest News for: chosa

Edit

CHOSA: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress (Chosa Oncology AB)

Public Technologies 19 Mar 2026
2026-03-19 08.45.00 CHOSA Oncology AB. CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress ... [email protected].
Edit

CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress (Chosa Oncology AB)

Public Technologies 19 Mar 2026
) CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress ... [email protected].
Edit

CHOSA: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy (Chosa Oncology AB)

Public Technologies 23 Jan 2026
2026-01-23 08.33.00 CHOSA Oncology AB ... Peter@chosa.bio ... As previously announced CHOSA is also exploring the predictive potential of the Cisplatin-DRP not only in cisplatin-treated patients but also in those treated with carboplatin in lung cancer.
Edit

Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy (Chosa Oncology AB)

Public Technologies 23 Jan 2026
Following publication, CHOSA intends to continue the patent process in selected jurisdictions while advancing development and validation of the technology and engaging with potential partners across pharmaceuticals, diagnostics and healthcare.
  • 1

Article Search

tools
×
×
×
×